Compare Brunswick Corporation (BC) vs Becton Dickinson and Co (BDX) Price & Performance

BC trades at $81.55, up 0.37% with a bullish technical signal. Recent Q2 2026 earnings beat estimates with EPS of $1.56 versus $1.19 expected. The company maintains a dividend of $0.44 per share and has strong analyst support with 22 buy ratings. However, negative net income margin and ROE highlight profitability challenges amid declining revenue trends from $6.8B in 2022 to $5.4B in 2025.

Outlook is cautiously optimistic due to earnings beats and institutional buying, but high P/E of 73.92 and persistent net losses pose valuation and execution risks. The consensus price target of $85.33 suggests modest upside, contingent on reversing profit declines and stabilizing cash flow.

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.